Professional Link
Get Instant Savings

The only oral therapy approved by the FDA for the treatment of Inflammatory Lesions (Red Bumps, Blemishes, Pustules) of Rosacea

Watch Commercial

Rosacea Photos: Before & After

The proof is in the pictures—ORACEA® (doxycycline, USP) Capsule delivers visible results

The patients pictured were actual participants in the rosacea treatment clinical trials for ORACEA®. Individual results may vary*.
Patient ID#: 301.115
*In this clinical trial, many study subjects demonstrated improvements in their rosacea over course of the study, and approximately 22% were clear or almost clear of disease symptoms by the end of the study.

*In this clinical trial, many study subjects demonstrated improvements in their rosacea over course of the study, and approximately 14% were clear or almost clear of disease symptoms by the end of the study.

This study was Phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of ORACEA®, in which patients received 40 mg of ORACEA® or a placebo for 16 weeks.

Important Safety Information

Important Safety Information: Oracea®

Oracea® is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. You may experience intestinal upsets, sore throat or sinus infections/sinusitis when taking Oracea®. Do not take Oracea® if you are allergic to tetracyclines, and it may cause harm to a developing fetus; so do not take Oracea® if you are pregnant or breastfeeding.

When taking Oracea®, stay out of direct or artificial sunlight, and make sure you tell your doctor if you have stomach or GI problems, kidney disease, have a yeast or fungal infection, take blood thinners, take oral contraceptives, or take medicine to treat acne, psoriasis or seizures. Oracea® does not treat bacterial infections. Use Oracea® only as prescribed by your doctor.

For more information about Oracea®, see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Important Safety Information: MetroGel® 1%

MetroGel® 1% is indicated for the topical treatment of the inflammatory lesions of rosacea. The following adverse experiences have been reported with the topical use of metronidazole: burning, skin irritation, dryness, transient redness, metallic taste, tingling or numbness of extremities and nausea. MetroGel® 1% is contraindicated in individuals with a history of hypersensitivity to metronidazole or any other ingredients in this formulation. For more information about MetroGel® 1%, see Full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

©2010 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective owners. This site intended for U.S. audiences only. Information in this website is not intended as medical advice. Talk to your doctor about medical concerns.